Introduction {#sec1}
============

Diabetes mellitus (DM), characterized by chronic hyperglycemia caused by deficiency in insulin secretion or resistance against insulin, is the most prevalent metabolic disorder worldwide, and it currently affects over 350 million people globally \[[@B1],[@B2]\]. So far, the exact underlying pathogenic mechanism of DM is still not fully understood. Nevertheless, the fact that over 100 genetic loci were already found to be correlated with an increased susceptibility to DM by past genome-wide association studies suggested that genetic factors were crucial for the occurrence and development of DM \[[@B3],[@B4]\].

Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is mainly expressed on activated T cells, and it serves a negative regulator of T cell activation and proliferation \[[@B5]\]. Previous studies showed that CTLA-4 could induce T cell tolerance and attenuate T cell mediated immune responses by binding with co-stimulating molecules, B7-1 (CD80) and B7-2 (CD86) \[[@B6]\], and dysfunction of CTLA-4 was demonstrated to be implicated in various autoimmune diseases including type 1 diabetes mellitus (T1DM) \[[@B7],[@B8]\]. Consequently, *CTLA-4* gene polymorphisms were intensively studied with regard to their associations with T1DM \[[@B9]--[@B12]\]. Recently, some pilot studies also analyzed potential associations between *CTLA-4* gene polymorphisms and the much more prevalent type 2 diabetes mellitus (T2DM) \[[@B13],[@B14]\]. Nevertheless, whether *CTLA-4* gene polymorphisms were associated with T1DM and T2DM or not remain controversial, especially when they were conducted in different populations. Therefore, we performed the present meta-analysis to pool the data of all relevant studies, and obtain more conclusive results on associations of *CTLA-4* gene polymorphisms with T1DM and T2DM.

Materials and methods {#sec2}
=====================

Literature search and inclusion criteria {#sec2-1}
----------------------------------------

The current meta-analysis was complied with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement \[[@B15]\]. Potentially relevant articles were searched in PubMed, Medline, Web of Science, and CNKI using the following key words: 'Cytotoxic T-lymphocyte antigen 4', 'CTLA-4', 'polymorphism', 'variant', 'mutation', 'genotype', 'allele', 'diabetes mellitus', 'diabetes', and 'DM'. The initial literature search was conducted in October 2018 and the latest update was performed in January 2019. We also screened the reference lists of all retrieved articles to identify other potentially relevant studies.

Included studies should met all the following criteria: (1) case--control study on associations between *CTLA-4* gene polymorphisms and individual susceptibility to DM; (2) provide adequate data to calculate odds ratios (ORs) and 95% confidence intervals (CIs); (3) full text in English or Chinese available. For duplicate reports, only the most complete one was included. Family-based association studies, case reports, case series, reviews, comments, letters, and conference presentations were excluded.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

The following data were extracted from included studies: (1) name of first author; (2) year of publication; (3) country and ethnicity of participants; (4) type of disease; (5) the number of cases and controls; and (6) genotypic distributions of *CTLA-4* gene polymorphisms in cases and controls. The probability value (*p* value) of Hardy--Weinberg equilibrium (HWE) test was also calculated.

The Newcastle--Ottawa scale (NOS) was used to assess the quality of eligible studies from three aspects: (1) selection of cases and controls; (2) comparability between cases and controls; and (3) exposure in cases and controls \[[@B16]\]. The NOS has a score range of 0--9, and studies with a score of more than 7 were assumed to be of high quality.

Two reviewers conducted data extraction and quality assessment independently. When necessary, the reviewers wrote to the corresponding authors for extra information. Any disagreement between two reviewers was solved by discussion until a consensus was reached.

Statistical analyses {#sec2-3}
--------------------

All statistical analyses in the present study were conducted with Review Manager Version 5.3.3 (The Cochrane Collaboration, Software Update, Oxford, United Kingdom). ORs and 95% CIs were used to assess potential associations of *CTLA-4* gene polymorphisms with the susceptibility to DM in dominant, recessive, over-dominant, and allele models, and a *P* value of 0.05 or less was considered to be statistically significant. Between-study heterogeneity was evaluated by *I*^2^ statistic. If *I*^2^ was greater than 50%, random-effect models (REMs) would be used for analyses due to the existence of significant heterogeneities. Otherwise, fixed-effect models (FEMs) would be employed for analyses. Subgroup analyses by ethnicity of participants were subsequently performed. Sensitivity analyses were carried out to test the stability of the results. Funnel plots were applied to evaluate possible publication biases.

Results {#sec3}
=======

Characteristics of included studies {#sec3-1}
-----------------------------------

Our systematic literature search yielded 842 results. After exclusion of irrelevant and duplicate articles by reading titles and abstracts, 135 potentially relevant articles were retrieved for further evaluation. Another 59 articles were subsequently excluded after reading the full text. Finally, a total of 76 studies that met the inclusion criteria of our meta-analysis were included (see [Figure 1](#F1){ref-type="fig"}). Characteristics of included studies are shown in [Table 1](#T1){ref-type="table"}. Figure 1Flowchart of study selection for the present study Table 1The characteristics of included studiesFirst author, yearCountryEthnicityType of diseaseSample sizeGenotypes (wtwt/wtmt/mtmt)*P* value for HWENOS scoreCasesControls**rs231775 A/G**Abe 1999JapanEast AsianT1DM111/44550/45/16177/207/610.9697Ahmadi 2013IranSouth AsianT1DM60/10725/32/367/36/40.7577Ahmedov 2006Azerbaijan RepublicCaucasianT1DM160/27180/58/22143/103/250.3077Awata 1998JapanEast AsianT1DM173/42572/80/21170/197/580.9387Balic 2009ChileMixedT1DM300/310125/136/39138/131/410.2677Baniasadi 2006IndiaSouth AsianT1DM130/18050/62/1876/79/250.5418Benmansour 2010TunisiaSouth AsianT1DM228/19398/83/47104/69/200.1027Bouqbis 2003MoroccoCaucasianT1DM118/11459/52/759/47/80.7427Caputo 2005ArgentinaMixedT1DM186/16876/84/2671/76/210.9247Çelmeli 2013TurkeyCaucasianT1DM91/9938/40/1343/49/70.1617Chen 2011ChinaEast AsianT1DM360/728199/136/25329/319/800.8398Cinek 2002Czech RepublicCaucasianT1DM305/289123/125/57106/133/500.4588Cosentino 2002ItalyCaucasianT1DM80/8521/55/440/40/50.2197Dallos 2008SlovakiaCaucasianT1DM171/23133/72/6655/126/500.1648Ding 2010ChinaEast AsianT1DM23/332/14/728/4/10.1267Djilali-Saiah 1998FranceCaucasianT1DM112/10037/41/3447/37/160.0707Donner 1997GermanyCaucasianT1DM293/32591/147/55135/149/410.9907Douroudis 2009EstoniaCaucasianT1DM170/23045/79/4668/125/370.1047Douroudis 2009FinlandCaucasianT1DM404/72569/203/132159/378/1880.2327Ei Wafai 2011Saudi ArabiaSouth AsianT1DM39/469/21/925/21/00.0457Fajardy 2002FranceCaucasianT1DM134/27341/76/1796/146/310.0277Ferreira 2009BrazilMixedT1DM49/4826/20/322/21/50.9977Genc 2004TurkeyCaucasianT1DM48/8024/20/443/34/30.2338Haller 2007EstoniaCaucasianT1DM131/25227/62/4277/135/400.1317Hauache 2005BrazilMixedT1DM124/7542/63/1930/34/110.7878Hayashi 1999JapanEast AsianT1DM117/14154/42/2172/47/220.0057Ide 2004JapanEast AsianT1DM116/11456/49/1134/59/210.6037Ihara 2001JapanEast AsianT1DM160/200NANANA7Ikegami 2006JapanEast AsianT1DM767/715439/285/43395/283/370.1317Jin 2015ChinaEast AsianT1DM402/482182/194/26169/241/720.3547Jung 2009KoreaEast AsianT1DM176/9094/58/2446/31/130.0537Kamoun 2001TunisiaSouth AsianT1DM74/4932/38/411/28/100.3167Kawasaki 2008JapanEast AsianT1DM91/36948/36/7122/186/610.4847Khoshroo 2017IranSouth AsianT1DM39/4011/10/1813/15/120.1147Kikuoka 2001JapanEast AsianT1DM125/20057/62/678/88/340.2878Klitz 2002USAMixedT1DM94/90NANANA7Korolija 2009CroatiaCaucasianT1DM102/19348/36/1896/84/130.3457Kumar 2015IndiaSouth AsianT1DM232/30595/101/36169/116/200.9877Lee 2000TaiwanEast AsianT1DM253/91150/85/1837/45/90.3787Lemos 2009PortugalCaucasianT1DM207/24982/95/30111/108/300.6377Liang 2004JapanEast AsianT1DM29/4019/10/010/27/30.0137Ma 2002ChinaEast AsianT1DM31/365/11/1519/9/80.0077McCormack 2001UKCaucasianT1DM144/307NANANA7Mochizuki 2003JapanEast AsianT1DM97/6044/36/1721/27/120.5397Mojtahedi 2005IranSouth AsianT1DM109/33121/78/10146/149/360.8267Momin 2009USAMixedT1DM261/280113/112/36131/119/300.7027Mosaad 2012EgyptSouth AsianT1DM104/7837/59/838/39/10.0107Nisticò 1996ItalyCaucasianT1DM483/529161/248/74236/242/510.3298Ongagna 2002FranceCaucasianT1DM62/8449/10/343/27/140.0137Osei-Hyiaman 2001JapanEast AsianT1DM350/420110/166/74201/177/420.7418Padma-Malini 2018IndiaSouth AsianT1DM196/19678/93/25128/61/70.9368Pérez 2009ChileMixedT1DM260/255116/110/34110/106/390.1157Philip 2011IndiaSouth AsianT1DM53/535/30/1832/15/60.0647Ranjouri 2016IranSouth AsianT1DM50/5036/12/241/7/20.0448Saleh 2008EgyptSouth AsianT1DM396/396166/175/55215/150/310.5017Song 2012ChinaEast AsianT1DM108/10073/25/1045/39/160.1387Steck 2005USAMixedT1DM102/198NANANA7Takara 2000JapanEast AsianT1DM74/10716/25/3334/43/300.0447Tavares 2015BrazilMixedT1DM204/30582/91/31127/140/380.9527Van der Auwera 1997BelgiumCaucasianT1DM525/530NANANA7Wang 2002ChinaEast AsianT1DM90/8413/54/2332/42/100.5007Wang 2008ChinaEast AsianT1DM48/1924/29/15124/52/160.0048Wood 2002GermanyCaucasianT1DM176/22059/84/3399/95/260.6627Xiang 2006ChinaEast AsianT1DM179/29079/86/1487/153/500.2168Yanagawa 1999JapanEast AsianT1DM110/20045/46/1978/88/340.2877Yang 2006ChinaEast AsianT1DM34/7123/8/332/28/110.2537Zalloua 2004USAMixedT1DM190/10291/75/2453/45/40.1377Ahmadi 2013IranSouth AsianT2DM56/10735/18/367/36/40.7577Ding 2010ChinaEast AsianT2DM34/3321/11/228/4/10.1267Gu 2007ChinaEast AsianT2DM111/3935/71/515/20/40.4757Haller 2007EstoniaCaucasianT2DM244/25276/122/4677/135/400.1317Jin 2015ChinaEast AsianT2DM330/482128/171/31169/241/720.3547Khoshroo 2017IranSouth AsianT2DM71/4039/17/1813/15/120.1147Kiani 2016IranSouth AsianT2DM111/10060/42/941/39/200.0667Ma 2002ChinaEast AsianT2DM31/367/17/719/9/80.0077Rau 2001GermanyCaucasianT2DM300/466126/140/34183/215/680.7078Shih 2018TaiwanEast AsianT2DM278/287118/127/33101/150/360.0847Uzer 2010TurkeyCaucasianT2DM72/16943/24/5113/45/110.0357Wang 2008ChinaEast AsianT2DM192/19259/102/31124/52/160.0048Yu 2006ChinaEast AsianT2DM121/3935/71/515/20/40.4757**rs5742909**Almasi 2015IranSouth AsianT1DM153/189143/10/0174/14/10.2357Balic 2009ChileMixedT1DM300/310243/50/7253/47/10\<0.0017Baniasadi 2006IndiaSouth AsianT1DM130/180113/15/2170/10/00.7018Benmansour 2010TunisiaSouth AsianT1DM228/193159/52/17156/29/8\<0.0017Bouqbis 2003MoroccoCaucasianT1DM118/114106/12/0110/4/00.8497Caputo 2007ArgentinaMixedT1DM178/136149/28/1110/26/00.2187Chen 2011ChinaEast AsianT1DM359/728281/71/7550/164/140.6648Douroudis 2009EstoniaCaucasianT1DM61/23052/8/1178/49/30.8577Ihara 2001JapanEast AsianT1DM160/200NANANA7Lee 2001TaiwanEast AsianT1DM347/260303/42/2201/56/30.6817Saleh 2008EgyptSouth AsianT1DM396/396180/178/38214/164/180.0537Steck 2005USAMixedT1DM102/198NANANA7Wang 2008ChinaEast AsianT1DM48/18930/18/0155/34/00.1748Zouidi 2014TunisiaSouth AsianT1DM76/16268/7/1145/15/20.0407Kiani 2016IranSouth AsianT2DM111/10075/26/1088/10/20.0207Shih 2018TaiwanEast AsianT2DM278/287227/49/2215/67/50.9337Uzer 2010TurkeyCaucasianT2DM72/16955/14/3116/43/100.0367Wang 2008ChinaEast AsianT2DM192/189157/35/0155/34/00.1748[^1]

CTLA-4 gene polymorphisms and the susceptibility to DM {#sec3-2}
------------------------------------------------------

Significant associations with susceptibility to T1DM were detected for rs231775 (dominant model: *P*=0.008, OR = 0.83, 95%CI 0.73--0.95; recessive model: *P*=0.003, OR = 1.27, 95%CI 1.09--1.50; allele model: *P*=0.004, OR = 0.85, 95%CI 0.77--0.95) and rs5742909 (recessive model: *P*=0.02, OR = 1.50, 95%CI 1.05--2.13) polymorphisms in overall population. Nevertheless, no any positive results were detected for T2DM in overall population.

Further subgroup analyses revealed that rs231775 polymorphism was significantly associated with susceptibility to T1DM in Caucasians (dominant, recessive, and allele models) and South Asians (dominant, recessive, over-dominant, and allele models), but not in East Asians. Moreover, rs231775 polymorphism was also significantly associated with susceptibility to T2DM in East Asians (over-dominant model) and South Asians (recessive and allele models), but not in Caucasians. Additionally, we also found that rs5742909 polymorphism was significantly associated with susceptibility to T1DM in South Asians (dominant, recessive, over-dominant, and allele models), but not in East Asians and Caucasians (see [Table 2](#T2){ref-type="table"}). Table 2Overall and subgroup analyses for *CTLA-4* gene polymorphisms and DMVariablesSample sizeDominant comparisonRecessive comparisonOver-dominant comparisonAllele comparison*P* valueOR (95%CI)*P* valueOR (95%CI)*P* valueOR (95%CI)*P* valueOR (95%CI)**rs231775 A/G***T1DM*Overall11420/146740.008[^\*^](#req-155660265815126140){ref-type="table-fn"}0.83 (0.73--0.95)0.003^[^\*^](#req-155660265815126140){ref-type="table-fn"}^1.27 (1.09--1.50)0.591.03 (0.93--1.13)0.004[^\*^](#req-155660265815126140){ref-type="table-fn"}0.85 (0.77--0.95)Caucasian3854/5102\<0.0001[^†^](#req-155660272375326140){ref-type="table-fn"}0.74 (0.67--0.81)\<0.0001[^†^](#req-155660272375326140){ref-type="table-fn"}1.61 (1.42--1.83)0.760.99 (0.90--1.08)\<0.0001[^†^](#req-155660272375326140){ref-type="table-fn"}0.77 (0.72--0.82)East Asian4024/56330.731.05 (0.80--1.37)0.780.95 (0.69--1.32)0.320.92 (0.77--1.09)0.791.03 (0.83--1.28)South Asian1710/2024\<0.0001[^†^](#req-155660272375326140){ref-type="table-fn"}0.52 (0.38--0.70)0.005[^\*^](#req-155660265815126140){ref-type="table-fn"}1.79 (1.19--2.70)0.001[^\*^](#req-155660265815126140){ref-type="table-fn"}1.47 (1.17--1.86)\<0.0001[^†^](#req-155660272375326140){ref-type="table-fn"}0.60 (0.48--0.75)*T2DM*Overall1951/22420.340.85 (0.61--1.19)0.121.16 (0.96--1.40)0.141.22 (0.94--1.59)0.580.94 (0.74--1.19)Caucasian616/8870.821.03 (0.83--1.27)0.750.95 (0.70--1.29)0.991.00 (0.81--1.23)0.751.03 (0.88--1.20)East Asian1097/11080.080.58 (0.32--1.07)0.590.88 (0.54--1.42)0.04[^‡^](#req-1556602703821261401){ref-type="table-fn"}1.66 (1.03--2.68)0.150.74 (0.49--1.12)South Asian238/2470.060.59 (0.34--1.02)0.02[^‡^](#req-1556602703821261401){ref-type="table-fn"}1.56 (1.08--2.27)0.360.84 (0.57--1.23)0.003[^\*^](#req-155660265815126140){ref-type="table-fn"}0.65 (0.49--0.87)**rs5742909 C/T***T1DM*Overall2656/34850.370.87 (0.65--1.18)0.02[^‡^](#req-1556602703821261401){ref-type="table-fn"}1.50 (1.05--2.13)0.511.10 (0.83--1.45)0.360.89 (0.70--1.13)Caucasian179/3440.770.78 (0.15--3.96)0.841.26 (0.13--12.34)0.801.25 (0.23--6.72)0.720.76 (0.17--3.36)East Asian914/13770.991.00 (0.47--2.14)0.740.87 (0.38--1.98)1.001.00 (0.47--2.13)0.801.07 (0.65--1.73)South Asian983/11200.0004[^§^](#req-155660270382126140){ref-type="table-fn"}0.68 (0.55--0.84)0.002[^§^](#req-155660270382126140){ref-type="table-fn"}2.05 (1.30--3.23)0.04[^‡^](#req-1556602703821261401){ref-type="table-fn"}1.27 (1.02--1.58)\<0.0001[^†^](#req-155660272375326140){ref-type="table-fn"}0.69 (0.58--0.82)*T2DM*Overall653/7450.800.92 (0.48--1.77)0.891.11 (0.27--4.65)0.931.02 (0.61--1.73)0.760.90 (0.47--1.74)East Asian470/4760.131.28 (0.93--1.75)0.290.41 (0.08--2.12)0.200.81 (0.59--1.12)0.111.27 (0.95--1.71)[^2][^3][^4][^5]

Sensitivity analyses {#sec3-3}
--------------------

Sensitivity analyses were carried out to test the stability of meta-analysis results by eliminating studies that deviated from HWE. No changes of results were detected for investigated *CTLA-4* gene polymorphisms in any comparisons, which indicated that our findings were quite statistically reliable.

Publication biases {#sec3-4}
------------------

Potential publication biases in the present study were evaluated with funnel plots. No obvious asymmetry of funnel plots was observed in any comparisons, which suggested that our findings were unlikely to be impacted by severe publication biases.

Discussion {#sec4}
==========

Despite enormous advancements in pharmacotherapy over the past few decades, DM and its associated vascular complications are still leading causes of death and disability all over the world \[[@B17],[@B18]\]. To date, the exact cause of DM is still largely unclear in spite of extensive investigations. However, the obvious familial aggregation tendency of DM indicated that genetic factors may significantly contribute to its occurrence and development \[[@B19]\]. Thus, identify potential genetic biomarkers is of particularly importance for an early diagnosis and a better prognosis of DM patients.

Previous studies showed that interferon α and its associated pathways could induce autoantigen presentation, active autoreactive monocytes, cytotoxic T-lymphocytes and NK cells, elicit endoplasmic reticulum stress of human islet B cells, and impair insulin production \[[@B20],[@B21]\]. These results indicated that autoimmunity might result in destruction of islet B cells, contribute to less insulin production, and give rise to the development of DM. As far as we know, this is so far the most comprehensive meta-analysis about *CTLA-4* gene polymorphisms and DM, and our pooled analyses revealed that rs231775 and rs5742909 polymorphisms may serve as genetic biomarkers of T1DM, and rs231775 polymorphism may also serve as a genetic biomarker of T2DM. The stabilities of synthetic results were evaluated by sensitivity analyses, and no alterations of results were observed in any comparisons, which suggested that our findings were statistically stable. As for evaluation of heterogeneities, significant heterogeneities were detected for rs231775 polymorphism in every comparison of overall analyses for T1DM, and thus all analyses were performed with REMs. But in further subgroup analyses, a reduction tendency of heterogeneity was found in South Asians, which suggested that differences in ethnicity could partially explain observed heterogeneities between studies.

There are several points that need to be addressed about the present study. First, our findings indicated that rs231775 and rs5742909 polymorphisms could be used to identify individuals at higher risk of developing T1DM, and rs231775 polymorphism could also be used to identify individuals at higher risk of developing T2DM. There are two possible explanations for our positive findings. First, rs231775 and rs5742909 polymorphisms of the *CTLA-4* gene may lead to alternations in gene expression or changes in CTLA-4 protein structure, which may subsequently affect biological functions of CTLA-4, result in immune dysfunction and ultimately impact individual susceptibility to DM, especially T1DM. Second, it is noteworthy that several analyses were still based on limited number of studies, and therefore, further replication studies, especially in T2DM are still warranted to confirm these findings. Third, the pathogenic mechanism of DM is extremely complex, and hence despite our positive findings, it is unlikely that a single genetic polymorphism could significantly contribute to its development \[[@B22],[@B23]\]. Fourth, due to lack of raw data, we failed to explore possible interactions of investigated *CTLA-4* gene polymorphisms. But to better illustrate the potential associations of *CTLA-4* gene polymorphisms with DM, we strongly recommend further studies to perform haplotype analyses and explore potential gene--gene interactions.

Our meta-analysis certainly has some limitations. First, although the general methodology qualities of included studies were good, it should be noted that we did not have access to genotypic distributions of investigated polymorphisms according to base characteristics of study subjects. Therefore, our results were derived from unadjusted estimations, and failure to conduct further adjusted analyses for baseline characteristics of participants such as age, gender, and co-morbidity conditions may influence the authenticity of our findings \[[@B24]\]. Second, significant heterogeneities were detected in certain subgroup comparisons, which indicated that the inconsistent results of included studies could not be fully explained by differences in ethnic background, and other unmeasured characteristics of participants may also partially attribute to between-study heterogeneities \[[@B25]\]. Third, associations between *CTLA-4* gene polymorphisms and DM may also be influenced by gene--environmental interactions. However, the majority of studies did not consider these potential interactions, which impeded us to perform relevant analyses accordingly \[[@B26]\]. Fourth, since only published articles were eligible for analyses, although funnel plots revealed no obvious publication biases, we still could not rule out the possibility of potential publication biases. Taken these limitations into consideration, the results of the present study should be interpreted with caution.

In conclusion, our findings indicated that rs231775 and rs5742909 polymorphisms may serve as genetic biomarkers of T1DM, and rs231775 polymorphism may also serve as a genetic biomarker of T2DM. Further well-designed studies, especially in T2DM are still warranted to confirm our findings, and future investigations also need to explore possible roles of other *CTLA-4* gene polymorphisms in DM.
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CI

:   confidence interval

CTLA-4

:   cytotoxic T-lymphocyte-associated antigen 4

DM

:   diabetes mellitus

HWE

:   Hardy--Weinberg equilibrium

NOS

:   Newcastle--Ottawa scale

OR

:   odds ratio

REM

:   random-effect model

T1DM

:   type 1 diabetes mellitus

T2DM

:   type 2 diabetes mellitus

[^1]: *Abbreviations*: wt, wild type; mt, mutant type; NA, not available.

[^2]: *P* \< 0.01.

[^3]: *P* \< 0.0001.

[^4]: *P* \< 0.05.

[^5]: *P* \< 0.001.
